Endocyte (ECYT) Shareholder Ra Capital Management Has Increased Stake; As Aflac (AFL) Market Value Declined, First Midwest Bank Trust Division Raised Stake

August 12, 2018 - By Margaret Guttierez

Aflac Incorporated (NYSE:AFL) Logo

Ra Capital Management Llc increased its stake in Endocyte Inc (ECYT) by 15.37% based on its latest 2018Q1 regulatory filing with the SEC. Ra Capital Management Llc bought 517,145 shares as the company’s stock rose 213.65% while stock markets declined. The hedge fund held 3.88M shares of the health care company at the end of 2018Q1, valued at $35.29M, up from 3.36 million at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Endocyte Inc for a number of months, seems to be bullish on the $1.12B market cap company. The stock decreased 2.21% or $0.36 during the last trading session, reaching $15.93. About 725,718 shares traded. Endocyte, Inc. (NASDAQ:ECYT) has risen 444.08% since August 12, 2017 and is uptrending. It has outperformed by 431.51% the S&P500. Some Historical ECYT News: 07/05/2018 – Endocyte Non-Deal Roadshow Scheduled By Wedbush for May. 14; 15/03/2018 – Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018; 09/05/2018 – Endocyte Provides First Quarter 2018 Financial Results and Operational Update; 09/05/2018 – ENDOCYTE – SUFFICIENT CASH TO FUND ACTIVITIES THROUGH EXPECTED END OF VISION TRIAL, POTENTIAL PROOF OF CONCEPT OF ITS EC17/CAR T-CELL THERAPY; 15/03/2018 – Endocyte Nominates Dawn Svoronos for Election to Its Bd of Directors and Announces Other Bd Developments; 15/03/2018 – ENDOCYTE INC – THREE OF CO’S CURRENT DIRECTORS INFORMED CO THAT THEY WOULD NOT STAND FOR RE-ELECTION AT 2018 ANNUAL MEETING; 15/03/2018 Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments; 09/05/2018 – Endocyte Has Cash to Fund Activities Through the Expected End of the VISION Trial and Potential Proof of Concept of Its EC17/CAR T-cell Therapy; 15/05/2018 – Ghost Tree Capital Buys New 3.2% Position in Endocyte; 19/04/2018 – DJ Endocyte Inc, Inst Holders, 1Q 2018 (ECYT)

First Midwest Bank Trust Division increased its stake in Aflac Inc (AFL) by 115.59% based on its latest 2018Q1 regulatory filing with the SEC. First Midwest Bank Trust Division bought 15,892 shares as the company’s stock declined 0.09% with the market. The institutional investor held 29,641 shares of the accident &health insurance company at the end of 2018Q1, valued at $1.30 million, up from 13,749 at the end of the previous reported quarter. First Midwest Bank Trust Division who had been investing in Aflac Inc for a number of months, seems to be bullish on the $35.69 billion market cap company. The stock decreased 0.60% or $0.28 during the last trading session, reaching $46.48. About 2.49M shares traded. Aflac Incorporated (NYSE:AFL) has risen 21.38% since August 12, 2017 and is uptrending. It has outperformed by 8.81% the S&P500.

More important recent Endocyte, Inc. (NASDAQ:ECYT) news were published by: Nasdaq.com which released: “Endocyte Announces Second Quarter 2018 Financial Results and Operational Update Call” on July 25, 2018, also Globenewswire.com published article titled: “Endocyte Provides Second Quarter 2018 Financial Results and Operational Update”, Globenewswire.com published: “Endocyte to Present at the 2018 Wedbush PacGrow Healthcare Conference” on August 08, 2018. More interesting news about Endocyte, Inc. (NASDAQ:ECYT) was released by: Globenewswire.com and their article: “Recent Analysis Shows Eaton Vance, Endocyte, Ion Geophysical, Macerich, SunCoke Energy, and Dolby Laboratories …” with publication date: August 03, 2018.

Ra Capital Management Llc, which manages about $1.48B and $1.31 billion US Long portfolio, decreased its stake in Avexis Inc by 142,989 shares to 1.03 million shares, valued at $127.08 million in 2018Q1, according to the filing. It also reduced its holding in Ascendis Pharma A S by 1.34M shares in the quarter, leaving it with 4.24M shares, and cut its stake in Sunesis Pharmaceuticals Inc.

Investors sentiment increased to 2.32 in 2018 Q1. Its up 0.96, from 1.36 in 2017Q4. It improved, as 10 investors sold ECYT shares while 12 reduced holdings. 27 funds opened positions while 24 raised stakes. 41.55 million shares or 108.70% more from 19.91 million shares in 2017Q4 were reported. Barclays Public Ltd accumulated 0% or 67,643 shares. California Employees Retirement has 258,100 shares. Captrust invested in 400 shares. Schwab Charles Invest Inc, California-based fund reported 11,300 shares. Morgan Stanley stated it has 197,919 shares or 0% of all its holdings. Goldman Sachs Gru Inc, New York-based fund reported 365,032 shares. Weiss Asset Mgmt LP holds 25,349 shares. Bessemer Gp invested in 1,500 shares or 0% of the stock. Bluecrest Cap has invested 0.05% in Endocyte, Inc. (NASDAQ:ECYT). Proshare Advisors Ltd Com has invested 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT). Panagora Asset Mngmt Inc holds 12,240 shares or 0% of its portfolio. 1.50M are held by Adage Capital Prns Gp Limited Liability Com. Northern Corporation holds 0% or 129,626 shares. Guggenheim Ltd Llc invested 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT). 76,936 were reported by Element Management Ltd Co.

Since March 9, 2018, it had 0 insider purchases, and 3 insider sales for $265,324 activity. The insider Leamon Christopher P sold 5,036 shares worth $45,677.

Among 6 analysts covering Endocyte (NASDAQ:ECYT), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Endocyte had 12 analyst reports since August 5, 2015 according to SRatingsIntel. Wedbush upgraded the shares of ECYT in report on Tuesday, October 3 to “Outperform” rating. The firm has “Outperform” rating given on Tuesday, February 27 by Cowen & Co. On Monday, June 5 the stock rating was downgraded by Cowen & Co to “Market Perform”. RBC Capital Markets maintained Endocyte, Inc. (NASDAQ:ECYT) rating on Wednesday, November 4. RBC Capital Markets has “Outperform” rating and $10 target. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. The rating was maintained by Cowen & Co with “Hold” on Friday, June 2. The stock has “Outperform” rating by Wedbush on Monday, July 16. The company was downgraded on Monday, June 5 by Wedbush. As per Monday, October 2, the company rating was maintained by Cowen & Co. On Wednesday, August 5 the stock rating was maintained by RBC Capital Markets with “Outperform”.

First Midwest Bank Trust Division, which manages about $725.39 million US Long portfolio, decreased its stake in Lockheed Martin Corp (NYSE:LMT) by 2,927 shares to 15,037 shares, valued at $5.08 million in 2018Q1, according to the filing. It also reduced its holding in Nextera Energy Inc (NYSE:NEE) by 2,898 shares in the quarter, leaving it with 29,461 shares, and cut its stake in Digital Rlty Tr Inc (NYSE:DLR).

Since February 16, 2018, it had 2 insider purchases, and 5 sales for $5.69 million activity. $2.88M worth of Aflac Incorporated (NYSE:AFL) was sold by KIRSCH ERIC M. HOWARD JUNE P also sold $239,194 worth of Aflac Incorporated (NYSE:AFL) shares. AMOS DANIEL P had sold 24,983 shares worth $2.24 million on Friday, February 16. Shares for $49,022 were bought by MOSKOWITZ JOSEPH L. Shares for $437,155 were sold by KNAPP CHARLES B. Lloyd Karole had bought 2,000 shares worth $178,090.

More important recent Aflac Incorporated (NYSE:AFL) news were published by: Fool.com which released: “3 Important Takeaways From Aflac’s 2nd Quarter” on August 09, 2018, also Fool.com published article titled: “3 Top Dividend Stocks With Yields Over 2%”, Seekingalpha.com published: “Aflac’s Q2 2018: A SWAN Stock” on July 28, 2018. More interesting news about Aflac Incorporated (NYSE:AFL) was released by: Seekingalpha.com and their article: “Aflac’s (AFL) CEO Daniel Amos on Q2 2018 Results – Earnings Call Transcript” with publication date: July 27, 2018.

Aflac Incorporated (NYSE:AFL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts